Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 12,892 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT01000883Recruiting
Biopsy study linking breast cancer tissue markers to treatment response
This study looks at breast cancer samples taken by biopsy to see how tissue “molecular markers” relate to how you respond to therapy and how the cancer behaves. It may help researchers better match future treatments to the biology of your tumor.
Chapel Hill, North CarolinaAges 18 years+ - NCT01173341Enrolling by invitation
Checking heart side effects of breast cancer treatments
This study looks at how breast cancer medicines affect the heart. It may help doctors better prevent, spot early, and manage heart side effects from trastuzumab and/or anthracycline chemotherapy.
Philadelphia, PennsylvaniaAges 18 years+ - NCT00033137Recruiting
Genetic study of Birt-Hogg-Dubé syndrome and kidney cancer risk
This research study examines the genes behind Birt-Hogg-Dubé (BHD) syndrome, a condition that increases kidney cancer risk. Researchers want to understand who inherits this condition and how to better identify and help people at risk.
Bethesda, MarylandAges 2 years+ - NCT00001186Recruiting
Camping for children and teens with cancer
This study looks at whether a special camp experience helps children and young adults with cancer feel better emotionally and socially. Campers participate in normal camp activities while receiving any medical care they need.
Bethesda, MarylandAges 7–25 - NCT02474160Recruiting
Banking cancer tissue and blood for future research
This study collects and stores leftover or newly taken samples of tissue and blood from people with cancer. The goal is to build a research library that can help investigators study cancer and develop better tests or treatments.
Birmingham, AlabamaAges 2 months+ - NCT07444541RecruitingPhase 1/Phase 2
Study drug with chemotherapy for advanced pancreatic cancer
This trial tests a new drug called ANO31905 given with standard chemotherapy for people with advanced pancreatic cancer that has a specific marker called CLDN18.2. The goal is to see if adding this drug works better than chemotherapy alone.
Los Angeles, CaliforniaAges 18 years+ - NCT07892573Recruiting
Drug combination for EGFR-positive advanced pancreatic cancer after prior treatment
This trial tests a new drug combination (becotatug vedotin, an immunotherapy called anti-PD-1, and a chemotherapy pill called S-1) for people with advanced pancreatic cancer that has EGFR protein and has already been treated with at least one standard therapy. The goal is to see if this combination can help shrink or control the cancer.
Ningbo, ZhejiangAges 18–85 - NCT07892755Recruiting
Blood test for early detection of uterine cancer
This study is testing a simple blood test to find signs of uterine (endometrial) cancer early. If you have been diagnosed with uterine cancer or a precancerous condition, or if you are healthy, you may be able to join and help improve how we screen for this cancer.
Guiyang, GuizhouAges Up to 18 years - NCT05076682RecruitingPhase 2
Study for hard-to-treat triple-negative breast cancer that keeps growing
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
ShanghaiAges 18–70 - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for cancers with a KRAS G12D mutation
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05645536Enrolling by invitationPhase 3
Safety follow-up for hormone-positive, HER2-negative breast cancer
This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.
Greenbrae, CaliforniaAges 18–51 - NCT05993923Recruiting
Geriatric team support for seniors having colorectal cancer surgery
This study tests whether a team of specialists (including a geriatric doctor) can help people aged 70+ recover better after colorectal cancer surgery. The goal is to see if this approach improves your daily functioning and independence after the operation.
Nîmes, FranceAges 70 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Phoenix, ArizonaAges 18 years+ - NCT07361510RecruitingPhase 3
Pumitamig vs Keytruda for advanced lung cancer with high PD-L1
This trial compares an experimental drug called Pumitamig with the approved immunotherapy drug Pembrolizumab (Keytruda) as the first treatment for advanced lung cancer that has high PD-L1 levels. The goal is to see which drug works better and has fewer side effects.
Daphne, AlabamaAges 18 years+ - NCT07518888Recruiting
Exercise and hormone changes for prostate cancer watch
This study looks at how exercise affects hormone levels in men with prostate cancer who are under active surveillance (watching the cancer without treating it yet). Participating might help you learn if exercise can improve your health and possibly delay the need for treatment.
Miami, FloridaAges 18–80 - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Birmingham, AlabamaAges 18 years+ - NCT07221357RecruitingPhase 2/Phase 3
Pumitamig plus chemo vs standard care for new colorectal cancer
This trial tests a new drug called Pumitamig combined with chemotherapy against standard bevacizumab plus chemotherapy for people with advanced colorectal cancer that cannot be surgically removed and hasn't been treated yet. The goal is to see which combination works better and is safer.
Tucson, ArizonaAges 18 years+ - NCT05920356RecruitingPhase 3
Tested KRAS-targeted sotorasib plus chemo vs pembrolizumab plus chemo
This Phase 3 trial tests whether sotorasib plus standard chemotherapy works better than pembrolizumab (an immunotherapy) plus standard chemotherapy as first treatment for certain advanced lung cancers. It may help people whose tumors have a KRAS G12C mutation and that do not show PD-L1 on testing.
Santa Barbara, CaliforniaAges 18–100 - NCT06899126RecruitingPhase 3
Study of a drug combo for first-line HER2-positive lung cancer
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
Anchorage, AlaskaAges 18 years+ - NCT07562152RecruitingPhase 3
Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
Huntsville, AlabamaAges 18 years+ - NCT07432802Recruiting
Comparing surgery and radiation for early-stage lung cancer
This study looks at two treatment options for early-stage lung cancer in patients who are considered 'high-risk' because of poor lung function or other health issues. The goal is to compare outcomes from a surgical approach (removing just the tumor and a small rim of tissue) versus a precise, shorter course of radiation therapy.
Copenhagen, CopenhagenAges 18 years+ - NCT07789912Recruiting
Proton radiation that avoids memory areas for cancer spread in the fluid
This study tests a special type of proton radiation that avoids the memory centers of the brain, called memory-avoidant proton craniospinal irradiation. It is for people with cancer that has spread to the fluid around the brain and spinal cord, and it aims to treat the cancer while potentially protecting memory and thinking.
Miami, FloridaAges 18 years+ - NCT07824882RecruitingPhase 2
New drug combo for advanced non-squamous lung cancer patients
This trial tests a new drug (HS-20093) alone versus combined with another drug (adebrelimab) for people with advanced or metastatic non-squamous non-small cell lung cancer who have already been treated. The goal is to see if the combination works better at shrinking tumors or slowing cancer growth.
Wuhan, HubeiAges 18 years+ - NCT05432804RecruitingPhase 1/Phase 2
Selinexor added to temozolomide for recurring brain glioblastoma
This trial studies whether adding selinexor to the standard chemotherapy temozolomide (with radiation) can better treat glioblastoma that has come back after prior treatment. If you meet specific tumor, health, and lab requirements, the goal is to slow tumor growth or improve symptoms.
Phoenix, ArizonaAges 18 years+
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 12,892 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.